Kornimate/medical-research-clean huggingface dataset:
improving quality of life and function for older cancer patients receiving radiotherapy

Conditions: Elderly; Cancer; Radiotherapy Side Effect

Summary: this study is a first part of a larger project aiming at improving the following outcomes in older cancer patients receiving external beam radiation therapy (ebrt): quality of life, functioning and need for professional help (dependency). to achieve this, the investigators will develop and test a geriatric assessment (ga) with management (gam) intervention targeting patients at risk of negative outcomes as defined. the problems and needs that older patients experience before, during and after ebrt are poorly described. furthermore, although ga is the recommended approach to assess older cancer patients' vulnerability, very few studies have investigated its benefit and feasibility in a radiotherapy setting and there is no universal recipe for how an efficient gam intervention should be applied in this setting. before defining and testing an intervention, the investigators will therefore conduct an observational study addressing older patients \>= 65 years referred for either palliative or curative ebrt. the main objectives are to identify patients at risk for negative outcomes, and to test the feasibility of ga in the community service and at a radiotherapy department.

ga includes a systematic assessment of area where older people often have problems, i.e. assessment of comorbidity, medication, functional status and physical functioning, cognitive function, nutritional status, and depression. in this observational study, the assessment will be performed using well-established instruments and tests before start and after completion of radiotherapy. the patient will be followed-up by repeated assessments at week 2, 8 and 16 post treatment. quality of life (qol) questionnaires will be filled in by self-report at the same points in time. follow-up data will also include information on the patients' use of health services (home-, nursing home and hospital care). additionally available diagnostic ct scans will also be used for analyses of nutritional status and body composition. eligible patients will be included at the radiotherapy unit, innlandet hospital trust after having given written informed consent. a project nurse (cancer nurse) will perform the assessments at the radiotherapy unit, whereas follow-up assessments will be performed by community cancer nurses. all municipalities in the hospital catchment area are invited to participate in the study. the study will be conducted in co-operation with several national and international partners, including partners from the local municipalities

Eligibility criteria:
inclusion criteria: * patients \>= 65 years of age * histologically confirmed cancer diagnoses * referred for palliative or curative ebrt * living in the hospital catchment area, able to understand and fill in self-report questionnaires * fluent in norwegian (orally and in writing), provide written, informed consent exclusion criteria:

Keywords: old elderly radiotherapy geriatric assessment
pharmacokinetics vancomycin cvvhdf with oxiris membrane

Conditions: AKI - Acute Kidney Injury

Summary: this study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (crrt) with the oxiris membrane. this membrane offers the added benefit of absorbing inflammatory cytokines. in vitro studies show that vancomycin is reduced by around 20 percent in patients using the an69st membrane, which is part of the oxiris membrane's structure. however, there is currently a lack of in vivo studies demonstrating the impact of the oxiris membrane on vancomycin levels. therefore, the hypothesis of this study is that vancomycin is also reduced by absorption in the oxiris membrane. this study measures the levels of vancomycin in these patients to determine the pharmacokinetic parameters.

this study monitors the levels of the maintenance dose of vancomycin in patients receiving continuous renal replacement therapy (crrt) with the cvvhdf mode using the oxiris membrane. blood samples were drawn from the a-line at the following time points: 0 (predose), 2, 3, 4, 5, 6, 8, and 12 hours after drug administration. the area under the curve (auc) of the drug was calculated using the phoenix winnonlin program. additionally, we reported the pharmacokinetic profile of this drug in patients with acute kidney injury (aki) undergoing crrt with the oxiris membrane.

Eligibility criteria:
inclusion criteria: * patients aged more than 18 years. * admitted to the intensive care unit of ramathibodi hospital. * under continuous renal replacement therapy (crrt) with cvvhdf using oxiris filter. * received vancomycin at least once after starting crrt with cvvhdf using oxiris filter. * who have signed the informed consent document. exclusion criteria: * patients with a history of vancomycin allergy. * patients expected to die within 24 hours after inclusion in study. * patients with circuit clotting occurring more than 2 hours during the blood draw period. * patients treated with extracorporeal membrane oxygenation (ecmo). * patients with a history of kidney transplantation. * pregnant or breastfeeding women. * patients who have decided to receive palliative care. * patients on hemodialysis or peritoneal dialysis.

Keywords: vancomycin crrt oxiris membrane
a study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy

Conditions: Drug-Resistant Epilepsy; Focal-Onset Seizures

Summary: the purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (psl) administered concomitantly with up to 3 anti-epileptic drugs (aeds) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.


Eligibility criteria:
inclusion criteria: * diagnosis of focal epilepsy per 1989 international league against epilepsy (ilae) criteria at least 3 years before study entry * subject has failed to achieve seizure control with \>=4 tolerated and appropriately chosen prior antiepileptic drugs (aed), including past and ongoing treatment, that were individually optimized for adequate dose and duration. prior discontinued aed treatment would need to be assessed by the investigator considering the patient medical records and patient and/or caregiver interview. 'prior aed' is defined as all past and ongoing aed treatments with a start date before the screening visit (visit 1) * average of \>= 4 spontaneous and observable focal seizures (type ia1 (i.e. focal aware), ib (i.e. focal impaired awareness), ic (i.e. focal to bilateral tonic-clonic)) per month * current treatment with an individually optimized and stable dose of at least 1 and up to 3 aeds for the 8 weeks prior to the screening visit with or without additional vagus nerve stimulation (vns) or other neurostimulation treatments exclusion criteria: * subject has a history of or signs of generalized or combined generalized and focal epilepsy * cluster seizures which are uncountable in the previous 8 weeks before study entry and during 4 weeks prospective baseline * current treatment with carbamazepine, phenytoin, primidone, phenobarbital * current treatment/ use of (non-aed) prescription, nonprescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the cyp3a4 or 2c19 pathway for 2 weeks (or 5 half-lives, whichever is longer) prior to the baseline visit * subjects taking sensitive substrates of cyp2c19 for 2 weeks (or 5 half-lives, whichever is longer) prior to the baseline visit * subject has been taking vigabatrin less than 2 years at study entry * subject has been taking felbamate for less than 12 months * subject taking retigabine for less than 4 years * current treatment with benzodiazepines (i.e. gaba-a-ergic drugs like zolpidem, zaleplon, or zopiclone, excluding gaba-a-ergic aeds) \<3 times per week for emergencies * subject has a current medical condition that occurred within the last 12 months which, in the opinion of the investigator, could compromise his/her safety or ability to participate in this study

Keywords: epilepsy padsevonil
immediate effects on gait and spasticity after the use of passive kinesiotherapy equipment in the lower limbs of neurological patients

Conditions: Hemiparesis; Paraparesis; Tetraparesis; Cerebral Palsy; Spastic Gait; Spasticity

Summary: undergo assessment of muscle tone (ashworth scale), gait (baiobit) and risk of falling (timed up and go) before using the device; use the device on the spastic lower limb(s) for 30 minutes; go through the same assessment carried out previously.


Eligibility criteria:
inclusion criteria: * agree and sign the free and informed consent form or signature of the person responsible * individuals with spasiticity (hemiparetic, paraparetic, tetraparetic and hemiparetic children with cerebral palsy) exclusion criteria: * over 18 years old whose ability to sign the free and informed consent form is compromised, or who understand it, but are not responsible for signing the free and informed consent form * present cardiovascular, neurological, musculoskeletal instability or other condition(s) that interfere with the use or positioning of the device or gait assessment * present cognitive deficits that interfere with understanding the icf and/or understanding how to carry out the protocol * for the children's group, participants who: 1) are under 8 years of age and/or over 13 years of age will be excluded; 2) no person responsible for signing the tcle; 3) present cognitive deficits that interfere with understanding the icf and/or understanding how to carry out the protocol

Keywords: gait spasticity passive kinesiotherapy spastic gait passive mobilization device
effect of emergency department bedside compression ultrasonography on door-to-disposition time in patients suspicious for lower extremity deep venous thrombosis

Conditions: Lower Extremity Deep Vein Thrombosis

Summary: comparing the disposition time of point of care ultrasound (pocus) versus formal lower extremity doppler in emergency department patients.


Eligibility criteria:
inclusion criteria: emergency department patients presenting for lower extremity swelling concerning deep vein thrombosis. - exclusion criteria: n/a -
sunface mirroring rct in brazil

Conditions: Skin Cancer

Summary: randomized trial looking at the effects of a behavioral photoaging software intervention on sunscreen use in the city of itauna, brazil.


Eligibility criteria:
inclusion criteria: visiting a secondary school in brazil. exclusion criteria: not visiting a secondary school in brazil.
comparison of stretching and met in lower cross syndrome

Conditions: Cross Syndrome

Summary: the aim of the study is to compare the effects of stretching exercises \& muscle energy techniques in the management of lower cross syndrome and to find the effective treatment in the lower cross syndrome management.

in 2015 the systematic review estimated that prevalence of chronic low back pain in 24 to 39 year old individual was 4.2% and the individual between 20 to 59 was 19.6% . the genesis and perpetuation of low back pain (lbp) has many underlying factors among which one is proposed by janda's concept of pelvic crossed syndrome. this condition describes a pattern of tight and weak muscles around the pelvis. marked postural deviation is seen such as increased lumber lordosis and depending on this lordosis the muscle involvement can be distinguished. the center of the gravity is slightly anterior to s1 or s2, which means pelvis position, is key to faulty or good alignment. various studies have been done on muscle imbalance lower crossed syndrome (lcs) using stretching and muscle energy technique (met). both have shown superior effects when compared to other treatment modalities/techniques. however there is paucity of literature on effectiveness of stretching and met in management of lcs.

Eligibility criteria:
inclusion criteria: * lcs pattern in standing position * patients having chronic low back pain * age : 20-50 years * both male and females * positive prone hip extension movement pattern test exclusion criteria: * fracture (wedge compression #) * inflammatory disorder * acute disc bulge * lumber instability * idiopathic scoliosis * patient with rheumatoid arthritis (ra) and other systemic diseases

Keywords: muscle energy technique lower cross syndrome stretching
record-vp: real-time evaluation of cardiac outpatient recording device with vitalpatch rtm

Conditions: Arrhythmias, Cardiac

Summary: the primary purpose of this study is to evaluate performance and safety of the vitalconnect platform when used for mobile cardiac telemetry (mct) or as an independent diagnostic testing facility (idtf) system during activities of daily living by subjects 18 years or older who have been recommended mct by their care provider.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2. if recommended mobile cardiac telemetry (mct) by the care provider 3. if instructed, be willing to record information such as daily activities and symptoms 4. able to speak, read, and write english. exclusion criteria: 1. have extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed wear sites; 2. have a known allergy to medical adhesives; 3. have any potentially life-threatening condition that (for example ventricular tachycardia or ventricular fibrillation), in the opinion of the investigator, would interfere with their participation in the study.

Keywords: arrhythmias real-time monitoring mobile cardiac telemetry vitalpatch independent diagnostic testing facility
the efficacy and safety of gemcitabine in combination with docetaxel to treat pancreatic or biliary cancer

Conditions: Pancreatic Neoplasms; Biliary Tract Neoplasms

Summary: the purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.

try a new drug association on this advanced cancer

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * patients must sign informed consent prior to study entry * patients has karnofsky performance status of more than 50% * no prior chemotherapy * histologically or cytologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease or biliary cancer * no previous radiotherapy for locally advanced or metastases. * hematopoietic: wbc \> 3000/mm2, absolute neutrophile count \> 1500/mm2, hemoglobin \> 9g/dl, platelet count \> 100 000/mm2 exclusion criteria: * no intracerebral or meningeal metastases * pregnant * fertile patient must use effective contraception * no other serious medical condition or illness that would preclude study participation * hepatic: bilirubin greater than upper limit of normal(uln) sgot and sgpt \> 3.5 times upper limit of normal(uln) alkaline phosphatase \> 6 times upper limit of normal(uln) * more than 30 days since prior investigational therapy

Keywords: pancreas or biliary cancer
aegr-733 and atorvastatin 20 mg vs. monotherapy in moderate hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to test the effectiveness of the study drug, aegr-733 alone and in combination with the medication, atorvastatin (lipitor), on cholesterol in volunteers with moderately high cholesterol.

recent studies suggest more intensive cholesterol lowering treatment for people at very high risk of a heart attack, specifically for patients who have heart disease plus major risk factors. available medications used alone at even the highest approved doses are not expected to reach these new target recommendations for cholesterol in a large number of subjects. thus, the development of new medications that can provide additional cholesterol lowering may be beneficial. this study tests the effectiveness of different doses of the study drug, aegr-733 alone and in combination with the approved cholesterol lowering drug, atorvastatin (lipitor), on cholesterol. volunteers will be randomized to one of 6 different study treatments and will take the assigned medication (3 capsules daily) for 8 weeks.

Eligibility criteria:
inclusion criteria: 1. men and women between the ages of 18 and 70 years. 2. elevated ldl cholesterol based on risk factors for cardiovascular disease or presence of cardiovascular disease exclusion criteria: 1. women who are pregnant, lactating, planning to become pregnant, or women of childbearing potential who have not successfully been using acceptable contraceptive methods over the previous 3 months, e.g., intrauterine device (iud) and barrier method plus spermicide. 2. uncontrolled hypertension 3. history of chronic kidney problems 4. history of liver disease 5. positive for hepatitis b or hepatitis c. 6. any major surgical procedure occurring less than 3 months ago 7. cardiac insufficiency 8. history of a malignant cancer (other than basal cell or squamous cell carcinoma of the skin that has been removed) within the previous 5 years. 9. regular alcohol use \>1 drink per day. 10. regular consumers of grapefruit juice, or currently taking the following medications: cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, hiv protease inhibitors, and nefazodone. 11. use of other cholesterol lowering medications that cannot be stopped. 12. heart attack or stroke within the previous 6 months 13. diabetes mellitus 14. body mass index (bmi) ≥ 40 kg/m2. 15. significant gastrointestinal symptoms, such as irritable bowel syndrome. 16. current use of fish oils, niacin, and herbal weight loss products that cannot be stopped.

Keywords: cholesterol
a study of re-treatment with mabthera (rituximab) in patients with rheumatoid arthritis who have had an inadequate response to a single anti-tnf inhibitor.

Conditions: Rheumatoid Arthritis

Summary: this single arm study will evaluate the efficacy and safety of repeated courses of mabthera in patients with active rheumatoid arthritis who have participated in ml19070, and have completed the week 24 visit. eligible patients (das28 \>2.6 after week 24), will receive 2 infusions of 1g mabthera (day 1 and day 15). for all patients in this extension study, up to 3 repeated courses of treatment are allowed. the anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients with rheumatoid arthritis who participated in ml19070, and have completed the week 24 visit; * eligible for re-treatment (das28 \>2.6 after week 24, swollen joint count \>=4, tender joint count \>=4). exclusion criteria: * patients who have withdrawn from treatment in ml19070 pre-week 16; * patients with a previous response in das28 \<0.6 to mabthera after week 16; * concurrent treatment with any dmard except for methotrexate, any tnf alpha inhibitor, or other biologic or investigational agent.
multi-model image of immunosuppressive agents in tao

Conditions: Thyroid Associated Ophthalmopathy

Summary: this study aims to evaluate the efficacy of immunosuppressive agents treating thyroid associated ophthalmopathy by multi-model image.

thyroid associated ophthalmopathy is one of autoimmune orbital diseases characterized by enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue volume affecting the appearance and visual function of the eyes. tao can be classified into active phase and inactive phase according to the activity score and wait-and-see or surgery are widely chosen for patients in inactive phase. a great number of patients in inactive phase becoming refractory and reoccurring. until now, the improvement of tao is still be measured subjectively with low reliability and less accuracy. multi-modal image is a new method to assess both the appearance and visual function of tao and some of the indexes can be regarded as more apparent and stable in assessing the efficacy and prognosis of tao. this perspective cohort study aims to evaluate the efficacy of immunosuppressive agents in tao by multi-model image and function assessments.

Eligibility criteria:
inclusion criteria: * informed consent * age 18-70 years old * diagnosed with tao. exclusion criteria: * contraindications to immunosuppressive agents. * patients with hiv, hepatitis b or c, tuberculosis or other active significant infection. * patients with severe chronic diseases in heart, lung, kidney and liver, which make it not tolerant to immunosuppressive agents. * patients have contraindications of mri(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination).

Keywords: thyroid associated ophthalmopathy immunosuppressive agents multi-modal image function assessment
effects of two hypocaloric diets on weight loss

Conditions: Obesity

Summary: the investigators evaluated whether an energy-restricted protein diet with low glycaemic index carbohydrates and soluble fibers (lc-p-lgi) would be more effective than a conventional diet (lc-conv) on weight-loss and related metabolic variables.

the subjects (9 men and 5 post-menopausal women) were randomly allocated, in a cross-over design, to two periods of 4 weeks of an energy restricted diet of 1200 kcal as either a conventional diet (lc- conv) or a special energy restricted diet compensated by proteins (lc-p-lgi). the two nutritional periods were separated by a wash-out interval of 8 weeks. before the start of the study, all subjects were instructed to maintain their usual lifestyle during the experimental period.anthropometric parameters, glucose and lipid homeostasis and inflammatory markers were evaluated before and after each dietary period.body fat and fat-free mass distributions were measured by a dual-energy x-ray absorptiometry (dxa, ge lunar prodigy corporation, madison, wi, usa) before and after each dietary period at the fasting state.

Eligibility criteria:
inclusion criteria: * bmi 26 to 35 kg/m2 * 25 to 60 years old * non diabetic subjects exclusion criteria: * sgot and sgpt \>2.5x the normal * plasma glucose more than 1.26 g/l * hepatic or renal or cardiac failure

Keywords: obesity dietary treatment high protein diet low glycaemic index adipocytes fat mass systemic inflammatory markers improvement of complications effect on weight loss
turkish acquired haemophilia registry

Conditions: Acquired Haemophilia

Summary: turkish acquired haemophilia registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in turkey.this is a multicentre, retrospective and prospective registry of subjects diagnosed and/or treated for acquired haemophilia. patients will be registered and the response to different therapies, details of each bleeding episode and the outcome of haemostatic and immunosuppressive therapy (ist) will be recorded. any male or female subject diagnosed with inhibitors to fviii or other factors and treated for acquired haemophilia can be entered on the registry. patients will be treated according to local practice. no additional tests or procedures are required by the registry. the retrospective period will not be time-limited and data will be collected from those recorded in the hospital notes. the prospective period will begin in september 1.2011, and will last for two years.


Eligibility criteria:
inclusion criteria: * acquired haemophilia diagnosis, written consent exclusion criteria: * being unable to give written consent

Keywords: acquired haemophilia factor viii